Eli Lilly reported stronger-than-expected quarterly results and raised its 2026 revenue forecast, driven by surging Zepbound and Mounjaro demand.
Eli Lilly’s latest earnings jump didn’t just beat expectations—it also changed the tone of the forecast, with management lifting full-year revenue guidance as sales momentum for Zepbound and Mounjaro accelerates.
In the first quarter. Misryoum reports that Lilly booked $19.80 billion in revenue. outpacing the market’s expectations and supporting a raised outlook for 2026 revenue to $82 billion–$85 billion.. The company also increased its adjusted profit range to $35.50–$37 per share. reflecting how demand for its GLP-1-linked therapies continues to outpace concerns about pricing.
What stands out is the speed at which the weight-loss and diabetes categories are scaling.. Misryoum details that Mounjaro generated $8.66 billion in sales for the quarter. up 125% year over year. while Zepbound delivered $4.16 billion in U.S.. revenue—up 80% year over year.. Even with lower realized prices—meaning the net price Lilly receives after discounts and other factors—volume growth helped carry results higher.
Misryoum also points to how U.S.. revenue climbed 43% to $12.1 billion, driven by a 49% increase in volume.. In plain terms: more prescriptions are being written, and more patients are being treated, even as prices adjust.. That combination—higher uptake paired with price pressure—is the central storyline shaping Lilly’s near-term numbers.
Zepbound and Mounjaro demand keeps beating pricing pressure
Misryoum notes that realized prices for Zepbound and another therapy for psoriatic arthritis were lower, partially offsetting the volume-led lift.. The result is an earnings profile that remains strong enough to support an upward revision to guidance—an important signal for investors watching whether the GLP-1 boom is maturing or simply shifting into a new phase.
For readers outside finance, the implication is straightforward: coverage, prescribing behavior, and product demand are moving together. When patients can access treatment—and clinicians feel confident prescribing it—sales growth often persists long enough to overwhelm price declines for a time.
The new factor: Lilly’s GLP-1 pill launch and the race for momentum
Even so. Foundayo is likely to dominate questions on Lilly’s call because the obesity pill category is entering a highly competitive sprint.. Misryoum describes that early prescription data suggest the initial rollout has been “modest. ” and the market will be watching whether momentum builds quickly enough to catch up with rivals that received earlier exposure.
This matters because the obesity market is not just about clinical efficacy—it’s also about adoption curves. Pills can reduce friction for some patients compared with injections, but adoption still depends on payer coverage, physician comfort, and patient willingness to start and stay on therapy.
Why Lilly’s raised forecast could reshape the GLP-1 business cycle
Analysts and investors often ask a simple question: when prices fall. does the market expand enough to keep revenue growth intact?. Lilly’s quarter suggests the answer, at least for now, is yes—because volume growth has been strong.. Management has also pointed to broader adoption trends. estimating that global GLP-1 use could rise from roughly 20 million patients at the end of last year to 30 million by the end of 2026.
There’s a broader social relevance to this.. As GLP-1 therapies spread. they influence healthcare spending patterns. insurance decision-making. and public conversations around obesity treatment being closer to mainstream chronic-care management.. That shift also raises practical questions for families: affordability. access. and whether coverage changes arrive fast enough to match the surge in demand.
Looking ahead. the next quarter and the next few months will likely be judged on two fronts: whether volume growth continues to offset pricing pressure. and whether Foundayo can translate early demand into sustained prescriptions.. If Lilly succeeds. Misryoum expects the story to move from “Can GLP-1 work at scale?” to “Which company captures the next layer of growth as the market expands and product formats multiply?”